Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) and Adherex Technologies (NASDAQ:FENC – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.
Volatility and Risk
Jaguar Animal Health has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Earnings & Valuation
This table compares Jaguar Animal Health and Adherex Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jaguar Animal Health | $11.51 million | 0.13 | -$53.43 million | ($3,731.33) | -0.00 |
| Adherex Technologies | $59.22 million | 6.13 | -$9.74 million | ($0.13) | -79.42 |
Adherex Technologies has higher revenue and earnings than Jaguar Animal Health. Adherex Technologies is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 0.1% of Jaguar Animal Health shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Jaguar Animal Health and Adherex Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jaguar Animal Health | -187.88% | N/A | -131.45% |
| Adherex Technologies | -6.09% | -5.71% | -2.37% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Jaguar Animal Health and Adherex Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
| Adherex Technologies | 1 | 1 | 4 | 0 | 2.50 |
Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 64.65%. Given Adherex Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than Jaguar Animal Health.
Summary
Adherex Technologies beats Jaguar Animal Health on 12 of the 14 factors compared between the two stocks.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
